J-WDMC Precision Therapeutics 

A Safe, Anti-Therapy Resistance, High Therapy Efficacy, Tumor-Specific ADC-Immunotherapy Drug to Cure Currently Incurable Cancer 

Tumor-Specific ADC-Immunotherapy Drug with Zero Normal Tissue Binding

        Our invention “Tumor-Specific ADC-Immunotherapy Drug” specifically targets tumor, zero normal tissue binding: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dosing and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dosing, thus have low therapy efficacies.

A Safe, Anti-Therapy Resistance, Tumor-Specific ADC-Immunotherapy Drug to Cure Currently Incurable Cancer

Current Antibody-Drug Conjugates (ADCs) often leak toxins into blood due to their cleavable linkers are pre-digested by cathepsin B in tumor microenvironment, leading to severe organ damage and life-threatening toxicities. Also, tumor efflux pumps expel these dugs, together, making only ~1% of administered drug dose accumulates in tumor, making cancer hard to cure. Thus, current drugs often give refractory late-stage patients only a few extra months of life. Our drug breaks these limitations.

Our non-cleavable ADC-Immunotherapy Drug ensures zero cathepsin B pre-digestion, it naturally binds, clusters, and destroys the centrosome microtubule structures of both tumor cells and tumor-associated macrophages (M2-TAMs)—eradicating tumors at their core.

# Breakthrough

1. Tumor-specific targeting with zero normal tissue binding, eliminating toxic side effects.

2. Native anti-tumor cells, anti-M2-TAM, microtubule-binding maximizing drug loading, and microtubule-attacking: No need for costly, complex genetic engineering, flexible linker, or multi-payload ADC design.

3. Inside tumor cells, it binds microtubules: (1) Resisting tumor efflux pumps, maximizing drug loading. (2) Blocking therapy resistance. (3) Naturally attacking microtubule.

4. Anti-Therapy Resistance: The target antigen is essential for tumor cell proliferation (mitosis) and survival, expressing in most cancers. Tumor cells cannot mutate it to resist our drug.

5. As an antibody platform, it natively penetrates into bone marrow and lymphatic systems to kill Lymphoma amp; Multiple Myeloma tumor cells: It is A CAR-T alternative.

6. Native anti-M2-TAM immunotherapy:

(1) Stop M2-TAM-induced regulatory T cells that protect tumor immunosuppressive shield.

(2) Reverse M2-TAM-induced CD8+ T cell dysfunction, reactivate them to kill tumor cells.

(3) Block M2-TAM-induced tumor CD47 Dont Eat Me Signal.

(4) Block M2-TAM-, MDSC-, and CAF-mediated tumor immunosuppression amp; their PD-L1/PD-1 tumor anti-T cell attack machinery.

(5) Stop M2-TAM-induced tumor growth, drug resistance, angiogenesis, tissue remodeling.

# By simply only targeting a single tumor antigen, our drug destroys multiple lifeblood pathways of cancer to eradicate tumors.

We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.      Antibody-image-guided precision cancer surgery.

2.      Antibody-image-guided precision external beam radiation therapy (EBRT).

3.      Antibody-targeted agent for Boron Neutron Capture Therapy (BNCT).

4.      Antibody-targeted proton and heavy-ion therapy.

5.      Antibody-contrast-enhanced CT, MRI, & PET tumor imaging. 

6.      CAR-T therapy and CAR-NK therapy.

7.      Antibody-cell conjugates (ACCs).

8.      T-cell receptor-mimic (TCRm) antibodies.

9.      Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

10.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

11.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

12.  Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

13.  Nanoparticles for targeted magnetic hyperthermia therapy & in situ vaccination.

14. Antibody-targeted ultrasound cancer therapy.

15.  Antibody-image-guided precision Interventional Oncology Therapy.

Contact: jiangmwd@gmail.com